Showing 1241-1250 of 5062 results for "".
- Demystifying Itch: Does S. aureus Kickstart a Molecular Chain Reaction That Culminates in the Urge to Scratch?https://practicaldermatology.com/news/demystifying-itch-does-s-aureus-kickstart-a-molecular-chain-reaction-that-culminates-in-the-urge-to-scratch/2462148/Staphylococcus aureus may cause itch by acting directly on nerve cells. The findings, based on research in mice and in human cells, are reported Nov. 22 in Cell. In eczema and atopic dermatitis, the equilibrium of microorganisms that keep skin he
- European Commission Approves EBGLYSS (Lebrikizumab) for Moderate-to-severe ADhttps://practicaldermatology.com/news/european-commission-approves-ebglyss-lebrikizumab-for-moderate-to-severe-ad/2462141/The European Commission has approved EBGLYSS (lebrikizumab) for the treatment of adult and adolescent patients (12 years and older with a body weight of at least 40 kg) with moderate-to-severe atopic dermatitis (AD), who are candidates for systemic therapy. Almirall will
- Is Lower Extremity Lymphedema a Risk for Skin Cancer?https://practicaldermatology.com/news/is-lower-extremity-lymphedema-a-risk-for-skin-cancer/2462127/Patients with lymphedema may have twice the risk of developing basal cell carcinomas and squamous cell carcinomas on the lower extremities than their counterparts without lymphedema, according to a retrospective study published in the November 2023 issue of the Mayo Clinic Proceedings.&n
- Super Melanin May Heal Skin Injuries From Sunburn, Chemical Burnshttps://practicaldermatology.com/news/super-melanin-may-heal-skin-injuries-from-sunburn-chemical-burns/2462125/A synthetic, biomimetic melanin may heal the damage that occurs when your skin is exposed to sunlight or environmental toxins. In a new study, Northwestern University scientists show that their synthetic melanin, mimicking the natural melanin in human skin, can be applied
- Revance's Erica Jordan Promoted to CCOhttps://practicaldermatology.com/news/revances-erica-jordan-promoted-to-coo/2462124/Erica Jordan is now Revance Therapeutics, Inc.’s Chief Commercial Officer (CCO), Aesthetics. “Given the importance of the DAXXIFY launch, I’m excited to elevate Erica to the position of Chief Commercial Officer, Aesthetics reporting directly to me. Having wo
- Survey: Americans with Mild-to-Moderate Acne Have Defeatist Attitudes About Treatment, Despite Self-Consciousnesshttps://practicaldermatology.com/news/sun-pharma-survey-reveals-americans-with-mild-to-moderate-acne-have-defeatist-attitudes-about-treatment-despite-self-consciousness/2462110/A new survey reveals defeatist attitudes about treatment among people with mild-to-moderate acne, despite feelings of self-consciousness. Among the 1,003 survey respondents ages 13-55, only three in 10 reported having seen a dermatologist, suggesting that many people with mild-to-moderate acne ar
- Tralokinumab Shows Improvements in Dupilumab Patients Up to 52 Weekshttps://practicaldermatology.com/news/tralokinumab-shows-improvements-in-dupilumab-patients-up-to-52-weeks/2462103/The results of a phase 3 trial expands on the efficacy and safety profile of tralokinumab, the first monoclonal antibody (mAb) that targets IL4Rα, blocking signaling of interleukin (IL)-13 and IL-4. Approved in the EU
- Biosimilar News: YUFLYMA Added to CarePartners Specialty Pharmacy Cost Savings Programshttps://practicaldermatology.com/news/biosimilar-news-yuflyma-added-to-carepartners-specialty-pharmacy-cost-savings-programs/2462100/Celltrion USA, Inc.’s US Food and Drug Administration-approved biosimilar, YUFLYMA (adalimumab-aaty) has been added to CarePartners Specialty Pharmacy Cost Savings Programs. YUFLYMA is a high-concentration (100mg/mL) and citrate-free formulation of the Humira (adal
- Study: Psoriasis Not Caused by Somatic Mutationshttps://practicaldermatology.com/news/study-psoriasis-not-caused-by-somatic-mutations/2462099/Psoriasis is not caused or spread by spontaneous genetic mutations in the skin, new research suggests. Researchers from the Wellcome Sanger Institute in Hinxton, U.K. and collaborators sequenced skin samples from 111 people with psoriasis. They didn’t find any mutated ge
- Psoriasis Pipeline Update: Will An Oral IL-23 Inhibitor Be the Next Psoriasis Blockbuster?https://practicaldermatology.com/news/psoriasis-pipeline-update-will-an-oral-il-23-inhibitor-be-the-next-psoriasis-blockbuster/2462098/Investigational JNJ-2113 is a novel oral interleukin (IL)-23R antagonist peptide that binds with high affinity to the IL-23R. It is the first and only targeted oral peptide designed to block the IL-23 receptor, which underpins the inflammatory response in psoriasis and other IL-23-